In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
The story of GraalVM in early 2026: a project settling into a quarterly cadence, tightening its support matrix, and—thanks to Oracle—being very explicit about what it is no longer going to be.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results